additional color
As you know, I have had a problem with the way GENR has worded some of their PR's for some time. Having worked in both the pharmaceutical industry (training sales reps on the medical aspects of drugs) and on the "front lines" in pharmacy, I understand how these companies market. If something is good, the hyperbole is unbounded. If the information is bad to marginal, the statements are positive, but subdued. GENR has chosen the subdued approach and this causes me to ask why. From the limited information that we are allowed to see (adding on the 10mg dose, giving only small dribs and drabs of clinical statistcs from the 10mg and 40mg dose, and the many departures) I can only guess that there is trouble. There may only be slight trouble, but for this company, that may be enough.
My reasons for buying in the first place (their total product line) has also come into question as cash flow issues have caused many programs to be abandoned or delayed.
Lastly, I had money tied up in this that I feel could be used in other personal ways. Also, claiming profit is a good thing. All signs led me to this decision.
I do hope that GENR does well. AMD needs as many potential cures as possible and GENR still holds promise. But my gut says that I should be watching this from a distance.
RPh
Market Data 
Markets 
AI
